Unlock stock picks and a broker-level newsfeed that powers Wall Street.
7 Small-Cap Stocks to Buy Now for Extraordinary Gains

In This Article:

September is living up to its reputation for being one of the worst months to own stocks. And here’s a spoiler alert…October isn’t shaping up to be much better. In fact, with interest rates likely to keep rising into 2023, an earnings recession is a near certainty. With that in mind, you’d have to be crazy to invest in small-cap stocks right now, right?

Yes and no. Small-cap stocks always carry outsized risk. And in bear markets that risk increases. But these are also frequently the stocks that offer investors the best chance for market-beating gains. And since these stocks tend to trade at a lower price than established blue-chip stocks, accumulating in bear markets may be a strategy that pays off handsomely down the road.

Guessing how long that road is or what twists and turns are still to come is a fool’s errand. So investing in small-cap stocks right now is only for the most risk-tolerant investors. Still, if that describes you and you have time on your side and are willing to put a small amount of capital at risk, here are seven small-cap stocks that have an opportunity to deliver extraordinary gains.

InvestorPlace - Stock Market News, Stock Advice & Trading Tips

CELU

Celuarity

$2.51

PLAY

Dave & Buster’s Entertainment

$32.24

SWBI

Smith& Wesson Brands

$10.35 

AXLS

Axcelis Technologies

$1.62

CWH

Camping World

$23.32

FTCI

FTC Solar

$3.17

UP

Wheels Up Experience

$1.36

Celularity (CELU)

Modern Medical Research Laboratory: Two Scientists Wearing Face Masks use Microscope, Analyse Sample in Petri Dish, Talk. Advanced Scientific Lab for Medicine, Biotechnology. Blue Color. KZR stock.
Modern Medical Research Laboratory: Two Scientists Wearing Face Masks use Microscope, Analyse Sample in Petri Dish, Talk. Advanced Scientific Lab for Medicine, Biotechnology. Blue Color. KZR stock.

Source: Gorodenkoff / Shutterstock.com

Like many biotechs, Celuarity (NASDAQ:CELU) is an early-stage biotech company. This means it has little to no revenue and is not yet profitable. Patience will be required because the company is not likely to be profitable for several years.

It does, however, have four oncology product candidates using its IMPACT platform in clinical trials with one entering Phase II. Celularity’s pipeline also includes two candidates for degenerative diseases that are still in the pre-trial stage.

CELU stock got a boost earlier in 2022 due in large part because the company received “fast track” designation for one of the products in its pipeline. However, broader concerns about risk-off assets have taken their toll on the stock.

In addition to time, bringing these candidates to market requires money. There also has been some concern about the company’s cash burn. However, the company recently entered into a $150 million pre-paid advance agreement with Yorkville that should alleviate some of those concerns.

Celuarity was founded in 2016 as a spin-off from Celgene and has only been publicly trading since 2019.